Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users

Synapse

Volumn 62, Issue 2, 2008, Pages 91-100

  McCann, Una D ^a,b   Kuwabara, Hiroto ^a   Kumar, Anil ^a   Palermo, Michael ^a   Abbey, Rubyna ^a   Brasic, James ^a   Ye, Weiguo ^a   Alexander, Mohab ^a   Dannals, Robert F ^a   Wong, Dean F ^a   Ricaurte, George A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Memory; Neurotoxicity; PET

Indexed keywords

DOPAMINE TRANSPORTER; METHAMPHETAMINE;

ADULT; AMNESIA; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; PRIORITY JOURNAL; PSYCHOMETRY; SEROTONINERGIC NERVE CELL; SHORT TERM MEMORY; SUBSTANCE ABUSE; WITHDRAWAL SYNDROME; WORKING MEMORY;

ADULT; AMPHETAMINE-RELATED DISORDERS; ANALYSIS OF VARIANCE; COCAINE; COGNITION; CORPUS STRIATUM; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; FEMALE; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE, SECONDARY; POSITRON-EMISSION TOMOGRAPHY;

EID: 37549062979     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20471     Document Type: Article

References (58)

1. Benton AL. 1969. Development of a multilingual aphasia battery: Progress and problems. J Neurol Sci 9:39-48.
2. Berg EA. 1948. A simple objective technique for measuring flexibility in thinking. J Gen Psychol 39:15-22.
3. Bolla KI, McCann UD, Ricaurte GA. 1998. Impaired memory function in abstinent MDMA ("Ecstasy") users. Neurology 51:1532-1537.
4. Bornstein RA, Leason M. 1985. Effects of localized lesions on the verbal concept attainment test. J Clin Exp Neuropsychol 7:421-429.
5. Broening HW, Pu C, Vorhees CV. 1997. Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell. Synapse 27:153-160.
6. CEWG (NIDA Community Epidemiology Work Group). 2005. Abuse of stimulants and other drugs. In: Epidemiologic trends in drug abuse, advance report and highlights/executive summary. Available at http://www.drugabuse.gov/PDF/CEWG/ AdvReport_Vol1_105.pdf (accessed Feb. 10, 2007).
7. Cropley VL, Fujita M, Innis RB, Nathan PJ. 2006. Molecular imaging of the dopaminergic system and its association with human cognitive function. Biol Psychiatry 59:898-907.
8. Gibb JW, Hanson GR, Johnson M. 1994. Neurochemical mechanisms of toxicity. In: Cho A, Segal DS, editors. Amphetamine and its analogs: Neuropsychopharmacology, toxicology and abuse. New York: Academic Press. p269-289.
9. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naïve Parkinson's disease: Implications for the symptomatic threshold. Neurology 48:1578-1583.
10. Halstead WC. 1947. Brain and intelligence. A quantitative study of the frontal lobes. Chicago, IL: University of Chicago Press.
11. Harvey DC, Lacan G, Melega WP. 2000. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure. Exp Brain Res 133:349-358.
12. Hoffman WF, Moore M, Templin R, McFarland B, Hitzemann RJ, Mitchell SH. 2006. Neuropsychological function and delay discounting in methamphetamine- dependent individuals. Psychopharmacology 188:162-170.
13. 11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab 23:1096-1112.
14. Johanson CE, Frey KA, Lundahl LH, Keenan P, Lockhart N, Roll J, Galloway GP, Koeppe RA, Kilbourn MR, Robbins T, Schuster CR. 2006. Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers. Psychopharmacology 185:327-338.
15. Kalechstein AD, Newton TF, Green M. 2003. Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. J Neuropsychiatry Clin Neurosci 15:215-220.
16. Kaplan E, Goodglass H, Weintraub S. 1976. Boston naming test, Experimental ed. Boston, MA: Boston University Aphasia Research Center.
17. Kish SJ, Shannak K, Rajput A, Deck JH, Hornykiewicz O. 1992. Aging produces a specific pattern of striatal dopamine loss: Implications for the etiology of idiopathic Parkinson's disease. J Neurochem 58:642-648.
18. Klove H. 1963. Clinical neuropsychology. In: Forster FM, editor. The medical clinics of North America. New York: Saunders. p1647-1658.
19. Kogan FJ, Nichols WK, Gibb JW. 1976. Influence of methamphetamine on nigral and striatal tyrosine hydroxylase activity and on striatal dopamine levels. Eur J Pharmacol 36:363-371.
20. Lew R, Malberg JE, Ricaurte GA, Seiden LS. 1997. Evidence for and mechanism of action of neurotoxicity of amphetamine related compounds. In: Kostrzewa RM, editor. Highly selective neurotoxins: Basic and clinical applications. Totowa: Humana Press. p 235-268.
21. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. 1997. Multimodality image registration by maximisation of mutual information. IEEE Trans Med Imaging 16:187-198.
22. McCann UD, Ricaurte GA. 2004. Amphetamine neurotoxicity: Accomplishments and remaining challenges. Neurosci Biobehav Rev 27:821-826.
23. 11C]WIN-35428. J Neurosci 18:8417-8422.
24. McCann UD, Mertl M, Eligulashvili V, Ricaurte GA. 1999. Cognitive performance in (±) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: A controlled study. Psychopharmacology (Berl) 143:417-425.
25. McKetin R, Mattick RP. 1997. Attention and memory in illicit amphetamine users. Drug Alcohol Depend 48:235-242.
26. McKetin R, Mattick RP. 1998. Attention and memory in illicit amphetamine users: Comparison with non-drug-using controls. Drug Alcohol Depend 50:181-184.
27. Melega WP, Quintana J, Raleigh MJ. 1996. 6-[18F]fluoro-l-DOPA-PET studies show partial reversibility of long-term effects of chronic amphetamine in monkeys. Synapse 22:63-69.
28. Melega WP, Raleigh MJ, Stout DB, Lacan G, Huang SC, Phelps ME. 1997. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res 766:113-120.
29. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. 2005. Implications of chronic methamphetamine use: A literature review. Harv Rev Psychiatry 13:141-154.
30. National Association of Counties. 2005. The meth epidemic in America: Two surveys of U.S. counties. Available at http://www.naco.org (accessed Feb. 11, 2007).
31. Nordahl TE, Salo R, Leamon M. 2003. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: A review. J Neuropsychiatry Clin Neurosci 15:317-325.
32. O'Callaghan JP, Miller D. 1994. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 270:741-751.
33. Paulus MP, Hozack N, Frank L, Brown GG, Schuckit MA. 2003. Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation. Biol Psychiatry 53:65-74.
34. Quednow BB, Jessen F, Kuhn KU, Maier W, Daum I, Wagner M. 2006. Memory deficits in abstinent MDMA (ecstasy) users: Neuropsychological evidence of frontal dysfunction. J Psychopharmacol 20:373-384.
35. Reitan RM, Wolfson D. 1993. The Halstead-Reitan neuropsychological test battery: Theory and clinical interpretation. Tucson, AZ: Neuropsychology Press.
36. Ricaurte GA, Schuster CR, Seiden LS. 1980. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study. Brain Res 193:153-163.
37. Ricaurte GA, Guillery RW, Seiden LS, Schuster CR, Moore RY. 1982. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res 235:93-103.
38. Salo R, Nordahl TE, Natsuaki Y, Leamon MH, Galloway GP, Waters C, Moore CD, Buonocore MH. 2007. Attentional control and brain metabolite levels in methamphetamine abusers. Biol Psychiatry 61:1272-1280.
39. SAMHSA (Substance Abuse and Mental Health Services Administration, Office of Applied Studies). 2005. National survey on drug use and health. Available at http://oas.samhsa.gov/WebOnly.htm#NHSDAtabs (accessed Feb. 10, 2007).
40. Seiden LS, Fischman MW, Schuster CR. 1976. Long-term methamphetamine induced changes in brain catecholamines in tolerant rhesus monkeys. Drug Alcohol Depend 1:215-219.
41. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N. 2001. Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214.
42. Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, Suzuki K, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Mori N. 2003. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 160:1699-1701.
43. Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, Futatsubashi M, Okada H, Minabe Y, Suzuki K, Iwata Y, Tsuchiya KJ, Tsukada H, Iyo M, Mori N. 2006. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arch Gen Psychiatry 63:90-100.
44. Simon SL, Domier C, Carnell J, Brethen P, Rawson R, Ling W. 2000. Cognitive impairment in individuals currently using methamphetamine. Am J Addict 9:222-231.
45. Stroop JR. 1935. Studies of interference in serial verbal reactions. J Exp Psychol 18:643-661.
46. The FIL Methods Group. 2003. Statistical parametric mapping software [computer program], Version 2.0. London, England: The FIL Methods Group.
47. Verbaten MN. 2003. Specific memory deficits in ecstasy users? The results of a meta-analysis. Hum Psychopharmacol 18:281-290.
48. Villemagne V, Yuan J, Wong DF. 1998. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: Evidence from [11C]WIN-35428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18:419-427.
49. Volkow ND, Chang L, Wang GJ. 2001a. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382.
50. Volkow ND, Chang L, Wang GJ. 2001b. Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21:9414-9418.
51. Ward J, Hall K, Haslam C. 2006. Patterns of memory dysfunction in current and 2-year abstinent MDMA users. J Clin Exp Neuropsychol 28:306-324.
52. Wechsler D. 1981. Manual for the Wechsler adult intelligence scale - Revised. New York, NY: Psychological Corp.
53. Wechsler D. 1987. Wechsler memory scale - Revised manual. New York, NY: Psychological Corp.
54. Wilson JM, Kalasinsky KS, Levey AI. 1996a. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703.
55. Wilson JM, Levey AI, Rajput A. 1996b. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47:718-726.
56. Woolverton WL, Ricaurte GA, Forno LS, Seiden LS. 1989. Long-term effects of chronic methamphetamine administration in rhesus monkeys. Brain Res 486:73-78.
57. Yui K, Ikemoto S, Ishiguro T, Goto K. 2000. Studies of amphetamine or methamphetamine psychosis in Japan: Relation of methamphetamine psychosis to schizophrenia. Ann NY Acad Sci 914:1-12.
58. Zakzanis KK, Campbell Z. 2006. Memory impairment in now abstinent MDMA users and continued users: A longitudinal follow-up. Neurology 66:740-741.